ARS Pharmaceuticals, Inc.

What they do

ARS Pharmaceuticals develops and sells neffy, a proprietary intranasal epinephrine formulation using an absorption enhancer called Intravail, for emergency treatment of Type I allergic reactions including anaphylaxis. neffy is approved in the United States (2 mg in August 2024; 1 mg in March 2025), the EU and UK as EURneffy, and in Japan, Australia, China and Canada. The company sells in the U.S. through a 106-person direct sales force targeting high-volume prescribers and an approximately 70-person co-promotion force with ALK U.S. targeting pediatricians, plus a virtual prescriber website (getneffy.com).

Revenue drivers

• U.S. neffy net product revenue — The company's only commercial product; Q2 2026 U.S. neffy net product revenue was $26.2 million. Total quarterly revenue was $33.7 million in Q2 2026. ARS cites approximately 3.3 million patients who fill an epinephrine prescription annually and an approximately $1.8 billion U.S. annual net sales opportunity at neffy's estimated gross-to-net yield.
• Field-targeted prescriber accounts — The company focuses on high-value epinephrine prescribers it says represent 44% of the total U.S. market opportunity, where it reported 8% market share in Q2 2026 versus 4% a year earlier.
• International neffy/EURneffy — EURneffy is approved in the EU and UK, and neffy 2 mg is approved in Japan, Australia and China; the company states it commercializes abroad through collaboration partners, so these contribute indirectly rather than through direct sales.
• Intranasal epinephrine platform (CSU) — A Phase 2b trial in chronic spontaneous urticaria is ongoing, with interim data expected in Q1 2027; no revenue today and no FDA-approved on-demand treatment currently exists for acute CSU flares.

Recent performance

Q2 2026 total revenue was $33.7 million, up from $22.7 million in Q1 2026, and included $26.2 million of U.S. neffy net product revenue. Revenue by quarter has been uneven: $32.5 million (Q3 2025), $28.1 million (Q4 2025), $22.7 million (Q1 2026), $33.7 million (Q2 2026). Full-year 2025 revenue was $84.3 million with a net loss of $171.3 million and negative operating cash flow of $170.9 million, versus 2024 net income of $8.0 million. As of June 30, 2026 the company reported total assets of $249.5 million, total liabilities of $237.0 million, shareholder equity of $12.5 million, cash and equivalents of $8.2 million and long-term debt of $96.7 million. Management said more than 35,000 healthcare providers have prescribed neffy to date, with approximately 167,000 U.S. patients prescribed as of the end of Q2 2026.

Strategy

The company is shifting from broad consumer-directed marketing to targeted engagement with high-volume prescribers, which it says represent 44% of the U.S. market opportunity. It has implemented a cost optimization framework to significantly reduce SG&A and says this supports an expected path to cash flow breakeven by the end of 2027. It completed expansion of its field sales organization and appointed Meg Smith as Chief Commercial Officer effective August 17, 2026, replacing the prior commercial leadership. It is advancing its intranasal epinephrine platform into chronic spontaneous urticaria, with interim Phase 2b data expected in Q1 2027. It continues to pursue payer coverage expansion across commercial plans and Medicaid, and has stated a goal of becoming the standard of care.

Risks

• Single-product concentration — neffy is the company's only approved product, so any shortfall in its commercial acceptance or adoption would directly and materially reduce revenue and results of operations.
• Limited commercial track record — ARS had no prior experience commercializing a product before neffy, and its own risk factors note numerous examples of unsuccessful launches by companies with more experience and resources.
• Payer coverage restrictions — Coverage is uneven: approximately 90% overall commercial coverage includes plans that may still require prior authorization, only about 57% of commercial coverage is without prior authorization, and just 9 of 50 Medicaid states cover neffy without prior authorization.
• Balance sheet and cash position — At June 30, 2026 the company reported $8.2 million of cash and equivalents, $12.5 million of shareholder equity and $96.7 million of long-term debt, leaving limited cushion relative to its operating losses.

Outlook

Management expects a significantly reduced operating expense base in the second half of 2026, supported by the shift to targeted provider engagement, and states an expected path to cash flow breakeven by the end of 2027. The company expects interim Phase 2b data in chronic spontaneous urticaria in Q1 2027 and characterizes CSU as a potential major growth opportunity on top of its existing commercial infrastructure. It also plans continued payer engagement to expand commercial and Medicaid coverage. No specific revenue or earnings guidance figures were provided in the excerpts.